Itil T M, Polvan N, Dincmen K, Egilmez S, Sungerbey K
Department of Psychiatry, New York Medical College, USA.
Dis Nerv Syst. 1974 Jul;35(7 Pt. 2):10-7.
Based on qualitative and quantitative EEG findings, the psychotropic properties of GB-94, GC-46, and GC-94 were predicted. According to the EEG model, GB-94 was predicted to be similar to amitriptyline and GC-46 t( imipramine. GC-94 was found to be much less effective on the CNS than GB-94 and GC-46 and was predicted to have "stimulatory" clinical effects similar to desipramine. The clinical trials demonstrated that GB-94 is indeed an antidepressive psychotropic compound similar to amitriptyline. GB-94 in lower dosages was also found to be effective in anxiety syndromes. In some schizophrenics GB-94 showed some therapeutic effects, while in others it obviously exacerbrated the psychotic symptomatology. GC-94 was not found to be significantly effective in a heterogenous psychiatric population. Only slight improvement in some schizophrenic patients was observed However, a noticeable worsening in the symptomatology of manic and hypomanic patients was seen. The study demonstarted that GC-94 indeed has a central stimulatory effect, but no minor or major tranquilizer properties or sedative antidepressive qualities were observed. GC-46 was tried in only three subjects. Based on this pilot trial, no conclusion can be made about the psychotropic properties of this compound. Our quantitative pharmaco-EEG and clinical trials clearly demonstrated the significant value of quantitative EEG in early screening of psychoactive drugs in order to predict their clinical values and effective dosage ranges.
基于脑电图的定性和定量结果,预测了GB - 94、GC - 46和GC - 94的精神药物特性。根据脑电图模型,预测GB - 94与阿米替林相似,GC - 46与丙咪嗪相似。发现GC - 94对中枢神经系统的作用远不如GB - 94和GC - 46有效,并预测其具有与地昔帕明相似的“刺激”临床效果。临床试验表明,GB - 94确实是一种类似于阿米替林的抗抑郁精神药物。还发现较低剂量的GB - 94对焦虑综合征有效。在一些精神分裂症患者中,GB - 94显示出一些治疗效果,而在另一些患者中,它明显加剧了精神病症状。在异质性精神病患者群体中,未发现GC - 94有显著疗效。仅观察到一些精神分裂症患者有轻微改善。然而,躁狂和轻躁狂患者的症状有明显恶化。研究表明,GC - 94确实具有中枢刺激作用,但未观察到其有轻微或主要的镇静特性或镇静抗抑郁作用。仅对三名受试者试用了GC - 46。基于这项初步试验,无法得出关于该化合物精神药物特性的结论。我们的定量药物脑电图和临床试验清楚地证明了定量脑电图在精神活性药物早期筛选中预测其临床价值和有效剂量范围的重要价值。